Pfizer Reports Q3 2026 Earnings
Date: November 3, 2026
Overview
Pfizer Inc. (PFE.US), a leading US pharmaceutical company, announced its Q3 2026 earnings, reporting a revenue of $16.6 billion and adjusted earnings per share (EPS) of $0.87. Both figures surpassed analysts' expectations, although they remained relatively flat compared to the previous year.
Financial Performance
The reported revenue of $16.6 billion exceeded the consensus estimate of $15.87 billion by approximately 4.6%. Adjusted EPS of $0.87 was 19% higher than the forecast of $0.73, although it did not show year-over-year growth. In contrast, GAAP EPS fell by 9% year over year to $0.56.
Sales from non-COVID products rose by 7% on an operational basis, indicating a positive trend in this segment, despite a decline in pandemic-related product sales that offset overall revenue growth.
Notably, revenue from newly launched and acquired products surged by 32% year over year, underscoring the increasing importance of Pfizer's expanding drug portfolio.
Guidance Update
Pfizer raised its full-year 2026 revenue guidance to a range of $62–64 billion, slightly above the consensus estimate of $62.17 billion. The midpoint of this range, $63 billion, suggests a 1.3% increase over analysts' expectations. Additionally, the adjusted EPS guidance was increased to $2.95–3.05, indicating stronger earnings prospects than previously anticipated.
Management highlighted advancements in its obesity treatment program and ongoing developments in oncology and immunology therapies, which are crucial for future growth as patent protections for older products expire.
Leadership Changes
Cecile Guegan was appointed as the new Chief Financial Officer (CFO) on November 1, 2026. This leadership change aligns with Pfizer's strategic focus on enhancing its drug portfolio and operational efficiency while meeting its upgraded financial targets.
Market Reaction
Following the earnings report, Pfizer shares remained stable, trading at approximately $30.70, marking a 17% increase over the past three months and a 26% rise over the past year. Despite this rebound, analysts have shown caution, with 15 downward revisions and only two upward revisions to EPS forecasts in the last 90 days.
A breakout above $31.50 per share could signal a bullish trend, as the stock is currently trading about 10% above its 200-day exponential moving average (EMA200).